



PERSONALIZED
MEDICINE COALITION

MEMBERSHIP PROSPECTUS

The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and health systems.



PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE OR NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on that assumption, some 20 institutions launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics.

Believing in an ecosystem of shared value across the multiple stakeholders it represents, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By combining data from diagnostic tests with an individual's medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans.

PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to advance strategic priorities in three areas:

- **Education:** To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers about how the field can make health systems more effective and efficient by targeting better treatments to only those patients who will benefit.
- **Advocacy:** To help facilitate the development of personalized medicine tests and therapies, PMC engages policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage and payment policies that support access to personalized medicine.
- **Evidence Development:** To encourage the swifter adoption of personalized medicine by health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”

– Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School

PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

MEMBER COMMITTEES/WORKING GROUPS

- **Public Policy Committee**
 - Patient Advocacy Organization Working Group
 - Pharma and Diagnostics Working Group
- **Science Policy Committee**
 - Health Care Working Group
 - Value Assessment Working Group
- **Ad Hoc Working Groups**
 - Health Data Working Group
 - Pharmacogenomics Working Group

MEMBER BENEFITS

**Contact
2,000+**

leaders in personalized medicine via PMC's member database

**Interact with
200+**

thought leaders from Congress, FDA, CMS and the private sector at member meetings and events

**Save
40%**

on registration for the Annual Personalized Medicine Conference

Attend Member Meetings and Events

at no charge

Discounted Subscription Offers

for outlets including *GenomeWeb*, *STAT*, and *The Journal of Precision Medicine*

Receive Copies

of PMC publications and reports

PMC MEMBERSHIP

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.

CLINICAL LABORATORY TESTING SERVICES

Dasman Diabetes Institute
Invitae
Laboratory Corporation of America (LabCorp)
Quest Diagnostics

DIAGNOSTIC COMPANIES

Admera Health
Agendia NV
Agilent Technologies
Alacris Theranostics GmbH
Almac Diagnostics
Asuragen
Caprion Proteomics
Caris Life Sciences
Circulogene
Cofactor Genomics
Diaceutics
Exact Sciences
Foundation Medicine, Inc.
GeneCentric Therapeutics
Genomind
GRAIL, Inc.
Guardant Health
IncellDx
Myriad Genetics
NanoString Technologies
NuProbe, Inc.
Olaris Therapeutics
Oncocyte
Personalis
QIAGEN, Inc.
Roche Diagnostics
RxGenomix
Scipher Medicine
Siemens Healthcare Diagnostics, Inc.
SomaLogic, Inc.
Thrive
Zionexa US Corporation

EMERGING BIOTECH/ PHARMACEUTICAL COMPANIES

Adaptive Biotechnologies
Elevation Oncology, Inc.
EQRx
Freenome
Helix
Immatics US
Legend Biotech
Regeneron
Tango Therapeutics
WuXi NextCODE

HEALTH INSURANCE COMPANIES

Harvard Pilgrim Health Care

INDUSTRY/TRADE ASSOCIATIONS

American Clinical Laboratory Association
BIO (Biotechnology Innovation Organization)
Biocom
PhRMA

IT/INFORMATICS COMPANIES

2bPrecise
Assurance Health Data
Change Healthcare
Concert Genetics
DNAnexus
Flatiron Health
GNS Healthcare
M2Gen
Medidata
P4-ML
Paige.ai
PathAI
PierianDx
Syapse
Translational Software
XIFIN, Inc.

LARGE BIOTECH/ PHARMACEUTICAL COMPANIES

AbbVie
Amgen, Inc.
AstraZeneca Pharmaceuticals
Bausch Health Companies
Bayer
Biogen
bluebird bio
Blueprint Medicines
Bristol-Myers Squibb
Eli Lilly and Company
Genentech, Inc.
Gilead
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Novartis
Pfizer, Inc.
Takeda Pharmaceuticals, Inc.

PATIENT ADVOCACY GROUPS

Accelerated Cure Project for Multiple Sclerosis
AiArthritis
Alliance for Aging Research
Alzheimer's Foundation of America
American Association of Kidney Patients (AAKP)
Bulgarian Association for Personalized Medicine
Canadian Organization for Rare Disorders
Cancer Commons
Clarity Foundation
Colorectal Cancer Alliance
CureDuchenne
Emily's Entourage
EveryLife Foundation For Rare Diseases
Fight Colorectal Cancer
Friends of Cancer Research

Global Liver Institute
GO₂ Foundation for Lung Cancer
HealthyWomen
International Cancer Advocacy Network (“ICAN”)
LUNgevity Foundation
Multiple Myeloma Research Foundation
National Alliance Against Disparities in Patient Health
National Alliance for Hispanic Health
National Health Council
National Patient Advocate Foundation
SynGap Research Fund
Team Trevor

PERSONALIZED MEDICINE SERVICE PROVIDERS

CareDx
Coriell Life Sciences
Genome Medical
Michael J. Bauer, M.D., & Associates, Inc.
Sema4
Sengenics
Tempus

RESEARCH, EDUCATION & CLINICAL CARE INSTITUTIONS

American Association for Cancer Research (AACR)
American Medical Association (AMA)
Arizona State University
American Society of Health System Pharmacists (ASHP)
Association for Molecular Pathology (AMP)
Brown University
Business Finland
Cancer Treatment Centers of America
Cello Health BioConsulting
College of American Pathologists
Colorado Center for Personalized Medicine

CommonSpirit Health
Coriell Institute for Medical Research
Duke Center for Research on Personalized Health Care
Essentia Institute of Rural Health
European Infrastructure for Translational Medicine
Harvard Business School
Hospital Albert Einstein
HudsonAlpha Institute for Biotechnology
iCAN
Instituto de Salud Carlos III
Intermountain Healthcare
Johns Hopkins Individualized Health
King Faisal Specialist Hospital and Research Centre
MaineHealth Accountable Care Organization
Manchester University School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson – Institute for Personalized Cancer Therapy
MITRE Corporation
Moffitt Cancer Center
Morehouse School of Medicine
National Pharmaceutical Council
Nicklaus Children’s Hospital Research Institute
North Carolina Biotechnology Center
NorthShore University HealthSystem
Precision Health Initiative at Cedars-Sinai
Qatar Biobank
Sanford Imagenetics, Sanford Health
Teachers’ Retirement System of Kentucky
The Christ Hospital

The Jackson Laboratory
Thomas Jefferson University
Translational Genomics Research Institute (Tgen)
UC Davis Mouse Biology Program
University of Alabama, Birmingham
University of California, San Francisco (UCSF)
University of Pennsylvania Health System
University of Rochester
University of South Florida Morsani College of Medicine
Vanderbilt University Medical Center
West Cancer Center

RESEARCH TOOL COMPANIES

Illumina, Inc.
Thermo Fisher Scientific

STRATEGIC PARTNERS

Accenture
Arnold & Porter
Artisan Healthcare Consulting
Bioscience Valuation BSV GmbH
Blue Latitude Health
Boston Healthcare Associates
Bradford Power
Bruce Quinn Associates
Cambridge Cancer Genomics
Cambridge Healthtech Institute
ConText
ConvergeHEALTH by Deloitte
Defined Health
EdgeTech Law, LLP
Foley & Lardner, LLP
Foley Hoag, LLP
Goldbug Strategies, LLC
Health Advances, LLC
Hogan Lovells, LLP
Innovation Horizons
Innovation Policy Solutions

Jane Binger, Ed.D.
Jared Schwartz, M.D.,
Ph.D., LLC
KPMG
L.E.K. Consulting
Michael Stocum
McDermott Will
& Emery
Neil A. Belson, LLC
Ogilvy
Priya Hays, M.D., Ph.D.

S.D. Averbuch
Consulting, LLC
Slone Partners
*The Journal of
Precision Medicine*
The Synergist
Truc Nguyen, M.D., Ph.D.
United States
Pharmacopeial
Convention (USP)
W20

William P. Stanford,
M.D., Ph.D.

VENTURE CAPITAL

GreyBird Ventures, LLC
Health Catalyst Capital
Management, LLC
Kleiner Perkins
Caufield & Byers
Section 32
Third Rock Ventures,
LLC

DUES STRUCTURE

As of January 2021

Large Public Corporation	\$29,000
Small Public Corporation	\$14,500
Trade Association	(based on revenues)
Private Corporation >50 FTEs	\$5,775
Professional Society	\$5,775
Private Corporation <50 FTEs	\$3,500
Strategic Partner	\$2,900
Research, Education & Clinical Care Institutions	\$2,900
Sole Proprietor	\$1,150
Patient Advocacy Group	\$500

Visit pmc.portal.membersuite.com to join the Coalition.

For more information, contact Kayla Smith,
Director, Membership & Development, at
ksmith@personalizedmedicinecoalition.org
or 202-589-0070.

STAFF

Edward Abrahams, Ph.D.
President

Cynthia A. Bens
*Senior Vice President,
Public Policy*

Daryl Pritchard, Ph.D.
*Senior Vice President,
Science Policy*

Faswilla Sampson, M.S.
Vice President, Operations

Christopher J. Wells, M.P.A.
Vice President, Public Affairs

Kayla Smith
*Director, Membership &
Development*

David L. Davenport
Manager, Public Policy

Lindsay Stephens
*Program Manager & Secretary
to the Board*

BOARD OF DIRECTORS

Jay G. Wohlgemuth, M.D.
Board Chair
Quest Diagnostics

William S. Dalton, Ph.D., M.D.
Board Vice Chair
M2Gen

Mark P. Stevenson, M.B.A.
Board Treasurer
Thermo Fisher Scientific

Michael Pellini, M.D., M.B.A.
Board Secretary
Section 32

Bonnie J. Addario
GO₂ Foundation for Lung Cancer

Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for
Translational Medicine (EATRIS)

Randy Burkholder
PhRMA

Stephen L. Eck, M.D., Ph.D.
MacroGenics

Lori Frank, Ph.D.
Alzheimer's Foundation
of America

Brad Gray
NanoString Technologies

Kris Joshi, Ph.D.
Change Healthcare

Peter Maag, Ph.D.
CareDx

Anne-Marie Martin, Ph.D.
GlaxoSmithKline

J. Brian Munroe
Bausch Health Companies

Lincoln Nadauld, M.D., Ph.D.
Intermountain Healthcare

Elizabeth O'Day, Ph.D.
Olaris, Inc.

Kimberly J. Popovits
Genomic Health

Hakan Sakul, Ph.D.
Pfizer, Inc.

Michael Sherman, M.D.
Harvard Pilgrim Health Care

Lauren Silvis
Tempus

**Apostolia M. Tsimberidou,
M.D., Ph.D.**
MD Anderson Cancer Center

Michael Vasconcelles, M.D.
Flatiron Health

Werner Verbiest
Janssen Pharmaceutical
Companies of Johnson
& Johnson



**PERSONALIZED
MEDICINE COALITION**

1710 Rhode Island Ave., NW, Suite 700
Washington, DC 20036

P: 202.589.1770

@permedcoalition